Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Hypogammaglobulinemia and bronchiectasis in mycophenolate mofetil-treated renal transplant recipients: an emerging clinical phenomenon?

Boddana P, Webb LH, Unsworth J, Brealey M, Bingham C, Harper SJ.

Clin Transplant. 2011 May-Jun;25(3):417-9. doi: 10.1111/j.1399-0012.2010.01255.x. Epub 2010 Apr 21.

PMID:
20438577
2.

Effect of mycophenolate mofetil on hematological side effects incidence in renal transplant recipients.

Sobiak J, Kamińska J, Głyda M, Duda G, Chrzanowska M.

Clin Transplant. 2013 Jul-Aug;27(4):E407-14. doi: 10.1111/ctr.12164. Epub 2013 Jun 13.

PMID:
23758434
3.

Mycophenolate mofetil and bronchiectasis in kidney transplant patients: a possible relationship.

Rook M, Postma DS, van der Jagt EJ, van Minnen CA, van der Heide JJ, Ploeg RJ, van Son WJ.

Transplantation. 2006 Jan 27;81(2):287-9.

PMID:
16436974
4.

Is mycophenolate mofetil less safe than azathioprine in elderly renal transplant recipients?

Johnson DW, Nicol DL, Purdie DM, Preston JM, Brown AM, Hawley CM, Campbell SB, Wall D, Griffin AD, Isbel NM.

Transplantation. 2002 Apr 15;73(7):1158-63.

PMID:
11965051
5.

Does mycophenolate mofetil increase the incidence of infections in stable renal transplant recipients initially treated with a two-drug regimen?

Chen Y, Chu SH, Wei TY, Yen TH, Chiang YJ, Wu CT, Chen HW.

Transplant Proc. 2004 Sep;36(7):2122-3.

PMID:
15518769
7.

Does mycophenolate mofetil increase the incidence of cytomegalovirus disease compared with azathioprine after cadaveric kidney transplantation?

Basic-Jukic N, Kes P, Bubic-Filipi LJ, Puretic Z, Brunetta B, Pasini J.

Transplant Proc. 2005 Mar;37(2):850-1.

PMID:
15848553
8.

A study comparing mycophenolate mofetil to azathioprine in simultaneous pancreas-kidney transplantation.

Odorico JS, Pirsch JD, Knechtle SJ, D'Alessandro AM, Sollinger HW.

Transplantation. 1998 Dec 27;66(12):1751-9.

PMID:
9884272
9.

Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation.

Neff RT, Hurst FP, Falta EM, Bohen EM, Lentine KL, Dharnidharka VR, Agodoa LY, Jindal RM, Yuan CM, Abbott KC.

Transplantation. 2008 Nov 27;86(10):1474-8. doi: 10.1097/TP.0b013e31818b62c8.

PMID:
19034021
10.

Analysis of a single-center experience with mycophenolate mofetil based immunosuppression in renal transplantation.

Triemer HL, Pearson TC, Odom KL, Larsen CP.

Clin Transplant. 2000 Aug;14(4 Pt 2):413-20.

PMID:
10946781
11.

Effect of mycophenolate mofetil on long-term outcomes in African american renal transplant recipients.

Meier-Kriesche HU, Ojo AO, Leichtman AB, Punch JD, Hanson JA, Cibrik DM, Kaplan B.

J Am Soc Nephrol. 2000 Dec;11(12):2366-70.

12.

Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years.

Grinyó JM, Gil-Vernet S, Cruzado JM, Caldés A, Riera L, Serón D, Rama I, Torras J.

Transpl Int. 2003 Nov;16(11):820-7. Epub 2003 Jul 22.

13.

[Infectious complications in using mofetil micofenolate in patients with renal allotransplant].

Prokopenko EI, Shcherbakova EO, Vatazin AV, Kruglov EE, Pasov SA, Budnikova NE, Agafonova SG, Rusanova EV.

Ter Arkh. 2005;77(1):67-72. Russian.

PMID:
15759459
14.

Immunoglobulin deficiency in kidney allograft recipients: comparative effects of mycophenolate mofetil and azathioprine.

Keven K, Sahin M, Kutlay S, Sengul S, Erturk S, Ersoz S, Erbay B.

Transpl Infect Dis. 2003 Dec;5(4):181-6.

PMID:
14987202
15.

Mycophenolate mofetil in pancreas transplantation.

Gruessner RW, Sutherland DE, Drangstveit MB, Wrenshall L, Humar A, Gruessner AC.

Transplantation. 1998 Aug 15;66(3):318-23.

PMID:
9721799
16.

Bronchiectasis diagnosed after renal transplantation: a retrospective multicenter study.

Dury S, Colosio C, Etienne I, Anglicheau D, Merieau E, Caillard S, Rivalan J, Thervet E, Essig M, Babinet F, Subra JF, Toubas O, Rieu P, Launois C, Perotin-Collard JM, Lebargy F, Deslée G; Spiesser group.

BMC Pulm Med. 2015 Nov 7;15:141. doi: 10.1186/s12890-015-0133-9.

17.

Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium.

Ortega F, Sánchez-Fructuoso A, Cruzado JM, Gómez-Alamillo JC, Alarcón A, Pallardó L, Morales JM, Oliver J, Guinea G; MYVIDA Study Group.

Transplantation. 2011 Aug 27;92(4):426-32. doi: 10.1097/TP.0b013e31822527ca.

PMID:
21760569
18.

Enteric-coated mycophenolate sodium: safe conversion from mycophenolate mofetil in maintenance renal transplant recipients.

Budde K, Glander P, Diekmann F, Dragun D, Waiser J, Fritsche L, Neumayer HH.

Transplant Proc. 2004 Mar;36(2 Suppl):524S-527S.

PMID:
15041401
20.

Adverse effects of mycophenolate mofetil in pediatric renal transplant recipients with presumed chronic rejection.

Butani L, Palmer J, Baluarte HJ, Polinsky MS.

Transplantation. 1999 Jul 15;68(1):83-6.

PMID:
10428272

Supplemental Content

Support Center